Wockhardt

Wockhardt's mission is to address unmet medical needs through research, with a strategic pivot towards combating the global crisis of antimicrobial resistance (AMR). Its key achievement is the development of a late-stage pipeline of novel antibiotic combinations, most notably Zaynich (WCK 5222), which has filed for marketing authorization in India, the US, and EU after a successful global Phase III trial. The company's strategy leverages its deep expertise in complex chemistry and anti-infective R&D to develop first-in-class therapies, while maintaining a foundation of diversified pharmaceutical businesses and hospital services to support its innovative endeavors.

Integrated R&D platform specializing in novel Beta-Lactam Enhancer (BLE) combinations and new chemical entities to overcome multi-drug resistant bacterial infections, complemented by biologics and complex generics capabilities.